Unveiling the cell wall-targeting mechanisms and multifaceted virulence modulation by a eugenol glycoconjugate against Aspergillus fumigatus: insights from in vitro and in ovo studies.

This article focuses on the antifungal effects and safety profile of compound 6i, a glycoconjugate of eugenol, against the pathogenic fungus Aspergillus fumigatus. The study demonstrates that compound 6i disrupts fungal cell wall integrity by inhibiting the biosynthesis of key components such as β-glucan, chitin, glycoproteins, ergosterol, and melanin, while modulating the expression of multiple genes and proteins involved in cell wall maintenance, conidiation, siderophore production, and signaling pathways including calcineurin and MAP kinase cascades. Proteomic and gene expression analyses revealed both downregulation and compensatory upregulation of various virulence factors, indicating a multifaceted mechanism of antifungal action. Importantly, toxicity assessments using a chick embryo in ovo model showed no adverse histopathological effects on liver, heart, or kidney tissues, suggesting compound 6i's potential as a safe antifungal candidate warranting further development for treating A. fumigatus infections.